Everyone wants to incorporate AI into model-informed drug development (MIDD), but the open question is how to do so while maintaining scientific rigor, transparency, and regulatory confidence. Join leaders from Pfizer, Bristol Myers Squibb, Incyte and Simulations Plus for a candid discussion of how organizations are approaching AI in MIDD: where it is already creating value, where the technology is evolving, and what it takes to integrate AI without compromising scientific or regulatory expectations. The panel will explore the practical decisions organizations are confronting as AI becomes part of scientific workflows, including:

• Where AI is delivering measurable value in MIDD today
• How organizations are approaching build, buy, and partner decisions
• What is required to integrate AI responsibly into scientific and regulatory workflows
• How the role of scientist is evolving, and which skills will become increasingly important

Whether you are already implementing AI or still defining your strategy, this conversation will help you identify the scientific, organizational and technology considerations that should shape your approach.

Panelists:

• John Mondick, Head of Clinical and Quantitative Science, Incyte
• Mohamed Shahin, AI Strategy Lead, Pfizer
• Anna Kondic, Vice President, Pharmacometrics, Translational Medicine and Clinical Pharmacology, Bristol Myers Squibb
• Amparo de la Peña, Vice President, Pharmacometric Services, Simulations Plus
• Jonathan Chauvin, Co-Chief Product & Technology Officer, Simulations Plus Moderator:
• Viera Lukacova, Chief Scientific Officer, Simulations Plus